E B Conemans1,2, G M Raicu-Ionita3, C R C Pieterman2, K M A Dreijerink2, O M Dekkers4, A R Hermus5, W W de Herder6, M L Drent7, A N A van der Horst-Schrivers8, B Havekes9, P H Bisschop10, G J Offerhaus3, I H M Borel Rinkes1, G D Valk2, H Th M Timmers11, M R Vriens12. 1. Department of Surgery, University Medical Center Utrecht, PO box 85500, 3508 GA, Utrecht, The Netherlands. 2. Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Endocrinology and Metabolism and Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. 5. Department of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. 7. Department of Internal Medicine, Section Endocrinology, VU University Medical Center, Amsterdam, The Netherlands. 8. Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands. 9. Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, Maastricht, The Netherlands. 10. Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands. 11. Section Stem Cells, Regenerative Medicine Center and Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. 12. Department of Surgery, University Medical Center Utrecht, PO box 85500, 3508 GA, Utrecht, The Netherlands. mvriens@umcutrecht.nl.
Abstract
PURPOSE: Pancreatic neuroendocrine tumors are a major manifestation of multiple endocrine neoplasia type 1 (MEN1). This tumor syndrome is caused by germline mutations in MEN1, encoding menin. Insight into pathogenesis of these tumors might lead to new biomarkers and therapeutic targets for these patients. Several lines of evidence point towards a role for p27Kip1 and p18Ink4c in MEN1-related tumor development in animal models for MEN1, but their contribution to human MEN1-related pancreatic neuroendocrine tumor development is not known. METHODS: In this study, we characterized protein expression of p27Kip1 and p18Ink4c in human MEN1-related PanNETs by immunohistochemistry. From the nationwide DutchMEN1 Study Group database including > 90% of the Dutch MEN1 population, MEN1-patients, who underwent pancreatic surgery, were selected. A tissue micro-array was constructed with available paraffin tissue blocks, and PanNETs from 61 MEN1 patients were eligible for analysis. RESULTS: Expression of p27Kip1 was high in 57 (93%) PanNETs and 67% of the tumors showed low expression of p18Ink4c (67.3%). No association was found between expression of either p27Kip1 or p18Ink4c and clinic-pathological characteristics. CONCLUSIONS: These findings indicate that loss of p18Ink4c, but not p27Kip1, is a common event in the development of MEN1-related PanNETs. Restoration of p18Ink4c function through CDK4/6 inhibitors could be a therapeutic option for MEN1-related PanNETs.
PURPOSE:Pancreatic neuroendocrine tumors are a major manifestation of multiple endocrine neoplasia type 1 (MEN1). This tumor syndrome is caused by germline mutations in MEN1, encoding menin. Insight into pathogenesis of these tumors might lead to new biomarkers and therapeutic targets for these patients. Several lines of evidence point towards a role for p27Kip1 and p18Ink4c in MEN1-related tumor development in animal models for MEN1, but their contribution to humanMEN1-related pancreatic neuroendocrine tumor development is not known. METHODS: In this study, we characterized protein expression of p27Kip1 and p18Ink4c in humanMEN1-related PanNETs by immunohistochemistry. From the nationwide DutchMEN1 Study Group database including > 90% of the Dutch MEN1 population, MEN1-patients, who underwent pancreatic surgery, were selected. A tissue micro-array was constructed with available paraffin tissue blocks, and PanNETs from 61 MEN1patients were eligible for analysis. RESULTS: Expression of p27Kip1 was high in 57 (93%) PanNETs and 67% of the tumors showed low expression of p18Ink4c (67.3%). No association was found between expression of either p27Kip1 or p18Ink4c and clinic-pathological characteristics. CONCLUSIONS: These findings indicate that loss of p18Ink4c, but not p27Kip1, is a common event in the development of MEN1-related PanNETs. Restoration of p18Ink4c function through CDK4/6 inhibitors could be a therapeutic option for MEN1-related PanNETs.
Authors: Hussein Raef; Minjing Zou; Essa Y Baitei; Roua A Al-Rijjal; Namik Kaya; Mohamed Al-Hamed; Dorota Monies; Nada N Abu-Dheim; Hindi Al-Hindi; Mohammed H Al-Ghamdi; Brian F Meyer; Yufei Shi Journal: Clin Endocrinol (Oxf) Date: 2011-12 Impact factor: 3.478
Authors: Maria A Kouvaraki; Jeffrey E Lee; Suzanne E Shapiro; Robert F Gagel; Steven I Sherman; Rena V Sellin; Gilbert J Cote; Douglas B Evans Journal: Arch Surg Date: 2002-06
Authors: Rick van Nuland; Arne H Smits; Paschalina Pallaki; Pascal W T C Jansen; Michiel Vermeulen; H T Marc Timmers Journal: Mol Cell Biol Date: 2013-03-18 Impact factor: 4.272
Authors: Hye Seung Lee; Min Chen; Ji Hun Kim; Woo Ho Kim; Soyeon Ahn; Kyungah Maeng; Carmen J Allegra; Frederic J Kaye; Steven N Hochwald; Maria Zajac-Kaye Journal: Int J Cancer Date: 2014-01-06 Impact factor: 7.396
Authors: R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano Journal: J Endocrinol Invest Date: 2022-08-30 Impact factor: 5.467
Authors: Paloma Cejas; Yotam Drier; Koen M A Dreijerink; Lodewijk A A Brosens; Vikram Deshpande; Charles B Epstein; Elfi B Conemans; Folkert H M Morsink; Mindy K Graham; Gerlof D Valk; Menno R Vriens; Carlos Fernandez-Del Castillo; Cristina R Ferrone; Tomer Adar; Michaela Bowden; Holly J Whitton; Annacarolina Da Silva; Alba Font-Tello; Henry W Long; Elizabeth Gaskell; Noam Shoresh; Christopher M Heaphy; Ewa Sicinska; Matthew H Kulke; Daniel C Chung; Bradley E Bernstein; Ramesh A Shivdasani Journal: Nat Med Date: 2019-07-01 Impact factor: 53.440
Authors: Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker Journal: Endocr Rev Date: 2021-03-15 Impact factor: 19.871
Authors: Dirk-Jan van Beek; Rachel S van Leeuwaarde; Carolina Rc Pieterman; Menno R Vriens; Gerlof D Valk Journal: Endocr Connect Date: 2018-09-01 Impact factor: 3.335